サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1735624

ヒト狂犬病ワクチンの世界市場規模：細胞株タイプ別、用途別、流通チャネル別、地域範囲別および予測

Global Human Rabies Vaccines Market Size By Cell Line Type, By Application, By Distribution Channel, By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
ヒト狂犬病ワクチンの世界市場規模：細胞株タイプ別、用途別、流通チャネル別、地域範囲別および予測
出版日: 2025年05月02日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒト狂犬病ワクチンの市場規模と予測

ヒト狂犬病ワクチンの市場規模は、2024年に12億3,000万米ドルと評価され、2026年から2032年にかけてCAGR 5.7%で成長し、2032年には19億1,000万米ドルに達すると予測されています。

  • ヒト狂犬病ワクチンは、ヒトが狂犬病ウイルスに感染するのを防ぐ生物製剤です。通常、不活化狂犬病ウイルス粒子またはウイルスから生成された組み換えタンパク質で構成されています。
  • これらのワクチン接種は、免疫系を刺激して狂犬病ウイルスに対する抗体を形成させ、将来の暴露から保護します。
  • ヒトの狂犬病ワクチンは、ウイルスに暴露された後、または獣医師、動物管理従事者、狂犬病が一般的な地域への旅行者など、狂犬病動物に遭遇するリスクが高い人の予防措置として、通常は腕に注射します。
  • さらに、ヒト狂犬病ワクチンは、狂犬病ウイルス感染による致死的な結果を防ぐ上で重要な役割を果たしています。

狂犬病ワクチンの世界市場力学

ヒト狂犬病ワクチン市場を形成している主な市場力学は以下の通りです：

主な市場促進要因

  • 世界の狂犬病罹患率の増加：世界の狂犬病発生率の増加：主にアジアとアフリカで、野良犬の襲撃による狂犬病発生率が世界的に急増していることが、ヒト狂犬病ワクチンの需要に拍車をかけています。狂犬病感染予防の取り組みにより、包括的なワクチン接種プログラムが求められており、市場拡大の原動力となっています。
  • 政府の取り組みとワクチン接種プログラム：狂犬病を撲滅するため、世界各国の政府が啓発・予防接種キャンペーンを開始しています。これらのプログラムでは、予防接種の無料化や助成が頻繁に実施されており、ヒト狂犬病ワクチンの使用や配布を促進する上で重要な役割を担っています。
  • ワクチン開発の進歩：細胞培養ワクチンや組み換えワクチンなど、より効率的な新しい狂犬病ワクチンの開発が市場を大きく押し上げています。これらのワクチンは安全性と有効性の特性が改善されており、より多くの採用と使用を促しています。
  • 狂犬病多発地域への旅行や曝露の増加：海外旅行、特に狂犬病が多発している地域では、狂犬病に感染する可能性が高くなります。このため、旅行者の間で曝露前予防が増加し、ヒト狂犬病ワクチンの需要が高まっています。

主な課題

  • 高コストと入手しやすさの問題：狂犬病ワクチンは高価であり、遠隔地や未開発地域では希少であるため、大きな障害となっています。こうした制約により、特に狂犬病が流行し、ワクチン接種が最も必要とされている地域では、重要なワクチン接種サービスへのアクセスが制限されています。
  • コールドチェーンの物流と保管：狂犬病ワクチンは、保管と輸送のためのコールドチェーンシステムが必要であるが、特に資源が乏しい地域では、その維持が困難です。コールドチェーンが切れるとワクチンの有効性が損なわれるため、大規模な予防接種キャンペーンの物流上の障害となり、市場の拡大が制限されます。
  • 認識と教育の欠如：多くの狂犬病流行地では、狂犬病とワクチン接種の意義に対する認識が低いです。この理解不足により、既存のワクチンが十分に使用されず、狂犬病の制圧と撲滅の試みが妨げられています。

主要動向：

  • 細胞培養ワクチンの出現：従来の卵を使った予防接種に代わるものとして、細胞培養ワクチンの人気が高まっています。細胞培養ワクチンは、より安全で効果が高く、副作用が少ないと考えられており、曝露前予防療法と曝露後療法の両方で人気が高まっています。
  • 予防接種とデジタル健康記録の統合：狂犬病予防接種を含む予防接種情報を追跡するために、デジタルヘルスプラットフォームの利用が増加しています。この統合により、ワクチンの接種率やスケジュールのモニタリングが改善され、予防接種プログラムの効率や患者のコンプライアンスが向上します。
  • ワクチンに関する官民パートナーシップ（PPP）：政府やヘルスケアグループは、狂犬病ワクチンの入手しやすさと購入しやすさを向上させるため、民間のワクチンメーカーと協定を結んでいます。このようなPPPは、十分なサービスを受けていない人々への予防接種プログラムを拡大し、狂犬病の制圧と撲滅に向けた世界の取り組みを強化することを目的としています。
  • 単回投与ワクチンの調査に重点を置く：研究開発の中心は、効果的な単回接種の狂犬病ワクチンの開発へと移りつつあります。単回投与ワクチンは、予防接種方法を簡素化し、コンプライアンス率を向上させ、曝露後の環境における反応時間を短縮する可能性があります。

目次

第1章 ヒト狂犬病ワクチンの世界市場導入

  • 市場の定義
  • 市場セグメンテーション
  • 調査スケジュール
  • 前提条件
  • 制限事項

第2章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • データの三角測量
  • ボトムアップアプローチ
  • トップダウンアプローチ
  • 調査の流れ
  • 業界専門家による主要な洞察
  • データソース

第3章 エグゼクティブサマリー

  • 市場概要
  • エコロジーのマッピング
  • 絶対的収益機会
  • 市場の魅力
  • ヒト狂犬病ワクチンの世界市場地域別分析
  • ヒト狂犬病ワクチンの世界市場：細胞株タイプ別
  • ヒト狂犬病ワクチンの世界市場：用途別
  • ヒト狂犬病ワクチンの世界市場：流通チャネル別
  • 今後の市場機会
  • 世界市場分割
  • 製品ライフライン

第4章 ヒト狂犬病ワクチンの世界市場展望

  • 世界のヒト狂犬病ワクチンの進化
  • 促進要因
    • 促進要因1
    • 促進要因2
  • 抑制要因
    • 抑制要因1
    • 抑制要因2
  • 機会
    • 機会1
    • 機会2
  • ポーターのファイブフォースモデル
  • バリューチェーン分析
  • 価格分析
  • マクロ経済分析

第5章 ヒト狂犬病ワクチンの世界市場：細胞株タイプ別

  • 概要
  • ニワトリ胚細胞
  • ベロ細胞
  • BHK細胞
  • その他

第6章 ヒト狂犬病ワクチンの世界市場：用途別

  • 概要
  • 曝露後予防
  • 曝露前予防

第7章 狂犬病ワクチンの世界市場：流通チャネル別

  • 概要
  • 病院薬局
  • 小売薬局
  • オンラインチャネル

第8章 ヒト狂犬病ワクチンの世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • ラテンアメリカ
    • ダウ・ケミカルブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • 中東・アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ
    • その他の中東・アフリカ

第9章 ヒト狂犬病ワクチンの世界市場競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な発展
  • 企業の地域別フットプリント
  • 企業の産業別フットプリント
  • ACEマトリックス

第10章 企業プロファイル

  • Sanofi Pasteur
  • Merck & Co.
  • GSK
  • Bavarian Nordic A/S
  • China National Biotec Group Co.
  • Wuhan Institute of Biological Products Co.
  • The Serum Institute of India Ltd.
  • Bharat Biotech International Limited
  • Valneva SE
  • Virbac SA

第11章 主な発展

  • 製品の上市／開発
  • 合併と買収
  • 事業拡大
  • パートナーシップと提携

第12章 ベリファイド・マーケット・インテリジェンス

  • VERIFIED MARKET INTELLIGENCEについて
  • ダイナミックなデータの可視化
目次
Product Code: 35766

Human Rabies Vaccines Market Size And Forecast

Human Rabies Vaccines Market size was valued at USD 1.23 Billion in 2024 and is projected to reach USD 1.91 Billion by 2032, growing at a CAGR of 5.7% from 2026 to 2032.

  • Human rabies vaccines are biologics that prevent humans from becoming infected with the rabies virus. They are usually composed of inactivated rabies virus particles or recombinant proteins produced from the virus.
  • These vaccinations stimulate the immune system to develop antibodies against the rabies virus, protecting against future exposure.
  • Human rabies vaccines are given in a series of injections, usually in the arm, after being exposed to the virus or as a preventive measure for people who are at high risk of encountering rabid animals, such as veterinarians, animal control workers, and travelers to areas where rabies is common.
  • Moreover, human rabies vaccines play an important role in preventing the potentially lethal consequences of rabies virus infection.

Global Human Rabies Vaccines Market Dynamics

The key market dynamics that are shaping the Human Rabies Vaccines Market include:

Key Market Drivers:

  • Growing Incidence of Rabies Worldwide: The global surge in rabies incidence, mainly in Asia and Africa as a result of stray dog attacks, has fueled demand for human rabies vaccines. Efforts to prevent rabies infections demand comprehensive vaccination programs, driving market expansion.
  • Government Initiatives and Vaccination Programs: To eradicate rabies, governments around the world have started awareness and immunization campaigns. These programs frequently feature free or subsidized immunization, which is critical in promoting the use and distribution of human rabies vaccines.
  • Advancements in Vaccine Development: The development of new and more efficient rabies vaccinations, such as cell culture and recombinant vaccines, has significantly boosted the market. These vaccines have improved safety and efficacy characteristics, encouraging greater adoption and use.
  • Increased Travel and Exposure to Rabies-Prone Areas: There's a greater chance of contracting rabies when traveling internationally, particularly in regions where the disease is more common. This has resulted in an increase in pre-exposure prophylaxis among travelers, fueling the demand for human rabies vaccines.

Key Challenges:

  • High Cost and Accessibility Issues: Rabies vaccines are expensive and scarce in remote or undeveloped areas, posing substantial obstacles. These constraints limit access to important vaccination services, particularly in locations where rabies is endemic and vaccinations are most needed.
  • Cold Chain Logistics and Storage: Rabies vaccines necessitate a cold chain system for storage and transportation, which is challenging to maintain, particularly in low-resource areas. Breaks in the cold chain jeopardize vaccine efficacy, creating a logistical obstacle for extensive vaccination campaigns and limiting market expansion.
  • Lack of Awareness and Education: Many rabies-endemic locations have a low level of awareness about the disease and the significance of vaccination. This lack of understanding resulted in the underuse of existing vaccines, impeding attempts to control and eradicate rabies.

Key Trends:

  • Emergence of Cell Culture Vaccines: Cell culture vaccines are becoming increasingly popular as an alternative to traditional egg-based immunizations. Cell culture vaccines are seen as safer, more effective, and have fewer side effects, making them increasingly popular in both pre-exposure prophylactic and post-exposure therapies.
  • Integration of Immunization with Digital Health Records: Digital health platforms are increasingly being utilized to track vaccination information, including rabies shots. This integration allows for improved monitoring of vaccine coverage and schedules, increasing the efficiency of immunization programs and patient compliance.
  • Public-Private Partnerships (PPPs) for Vaccine Accessibility: Governments and healthcare groups are forging agreements with private-sector vaccine makers to improve rabies vaccine accessibility and affordability. These PPPs seek to expand immunization programs to underserved groups, thereby strengthening worldwide efforts to control and eliminate rabies.
  • Focus on Research for Single-Dose Vaccines: Research and development efforts are increasingly centered on developing effective single-dose rabies vaccinations. A single-dose vaccine would simplify immunization methods, enhance compliance rates, and potentially accelerate response times in post-exposure settings, all of which would have a substantial impact on public health outcomes.

Global Human Rabies Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the Human Rabies Vaccines Market:

Asia Pacific:

  • According to Verified Market Research, Asia Pacific is estimated to dominate the Human Rabies Vaccines Market during the forecast period. Asia Pacific has some of the highest rates of rabies globally, partly due to massive stray dog populations in countries like India and China. This high frequency creates a significant need for human rabies vaccines, making the region an important market for these products.
  • Governments in the Asia Pacific region have initiated aggressive rabies control and elimination programs, including mass vaccination of animals and humans. These measures considerably contribute to increased demand for rabies vaccines, which strengthens the market in this region.
  • In the Asia Pacific region, public awareness of rabies and its prevention is increasing, due in part to educational efforts launched by health organizations and governments. This increased awareness has resulted in greater vaccination rates, which is fueling the market's growth.
  • Furthermore, the Asia Pacific region's rapid development and extension of healthcare infrastructure, including increasing healthcare spending and the formation of new healthcare institutions, has expanded public access to vaccines. This infrastructure expansion enables more widespread distribution and administration of rabies vaccines.

Latin America:

  • The expansion of urban areas in Latin America has resulted in more pet ownership and interaction with wildlife, increasing the danger of rabies spread. This tendency increases demand for pre-exposure prophylactic and post-exposure therapies, hence expanding the Human Rabies Vaccines Market.
  • Many Latin American countries have carried out large rabies vaccination efforts for both animals and humans, particularly in rural and urban peripheral areas. These government-led programs are critical drivers of increased demand and distribution of rabies vaccines throughout the region.
  • Furthermore, in Latin American countries, the growth of healthcare services and improved access to medical care have permitted increased vaccination coverage. This includes rural healthcare programs and the creation of clinics in underserved areas, which will drive the demand for rabies vaccines by making them more accessible to a larger population.

Middle East & Africa:

  • The Middle East and Africa region has a high incidence of rabies cases, mostly due to stray dog populations and animals. This prevalence needs the continued and growing use of rabies vaccines, which drives market growth in both preventive and post-exposure therapies.
  • Several nations in the region have initiated attempts to eradicate rabies, such as mass vaccination of animals and public health campaigns urging immunization. These initiatives by governmental and non-governmental organizations have considerably increased the demand for human rabies vaccines.
  • Furthermore, International health organizations and philanthropists are increasingly sponsoring rabies prevention and control projects throughout the Middle East and Africa. This external financing and technical aid make vaccine procurement and distribution easier, increasing the region's ability to effectively combat rabies.

Global Human Rabies Vaccines Market: Segmentation Analysis

The Global Human Rabies Vaccines Market is segmented based on Cell Line Type, Application, Distribution Channel, And Geography.

Human Rabies Vaccines Market, By Cell Line Type

  • Chick Embryo Cell
  • Vero Cell
  • BHK Cell
  • Others

Based on Cell Line Type, the market is segmented into Chick Embryo Cells, Vero Cells, BHK Cells, and Others. The chick embryo cell segment is estimated to dominate the Human Rabies Vaccines Market due to the long-standing usage of chick embryo cells in the manufacture of rabies vaccines, which are known for their efficacy and safety. Vaccines made from chick embryo cell culture are widely used in immunization programs around the world, thanks in part to their long history of usage and thorough safety data. Furthermore, the synthesis procedure employing chick embryo cells is cost-effective and well-optimized, making these vaccines accessible and economical for large-scale immunization programs, particularly in underdeveloped countries where rabies is prevalent.

Human Rabies Vaccines Market, By Application

  • Post-exposure Prophylaxis
  • Pre-exposure Prophylaxis

Based on Application, the market is segmented into Post-exposure Prophylaxis and Pre-exposure Prophylaxis. The post-exposure prophylaxis segment is estimated to dominate the Human Rabies Vaccines Market during the forecast period due to the critical requirement for rabies vaccination following potential exposure to the rabies virus, which can be acquired by bites or scratches from infected animals. In many areas, particularly those where rabies is endemic, the danger of exposure is considerable, demanding early treatment to avoid the development of the disease, which is almost invariably fatal once symptoms appear. Post-exposure prophylaxis (PEP) entails delivering the rabies vaccination soon after exposure to prevent the virus from developing into an active disease.

Human Rabies Vaccines Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channel

Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Channel. The hospital pharmacies segment is estimated to dominate the Human Rabies Vaccines Market during the forecast period due to the essential role hospital pharmacists play in administering post-exposure prophylaxis (PEP), which needs prompt medical attention. Hospitals are the major treatment locations for rabies exposures because they can give both the vaccination and the required immunoglobulins, as well as skilled medical monitoring. Furthermore, in many locations, rabies vaccines are provided as part of government-led health campaigns, with hospitals serving as the primary distribution and administration sites.

Key Players

  • The "Human Rabies Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sanofi Pasteur, Merck & Co., GSK, Bavarian Nordic A/S, China National Biotec Group Co., Wuhan Institute of Biological Products Co., The Serum Institute of India Ltd., Bharat Biotech International Limited, Valneva SE, Virbac SA, Crucell NV, Institute of Viral Diseases and CanSino Biologics Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Human Rabies Vaccines Market Recent Developments
  • In December 2022, Everest Medicines announced the launch of a novel mRNA Rabies Vaccine development and the completion of a preclinical proof-of-concept study. This is a collaboration with Providence Therapeutics that focuses on a new rabies vaccine candidate.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMAN RABIES VACCINES MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Human Rabies Vaccines Market Geographical Analysis (CAGR %)
  • 3.6 Global Human Rabies Vaccines Market, By Cell Line Type (USD Million)
  • 3.7 Global Human Rabies Vaccines Market, By Application (USD Million)
  • 3.8 Global Human Rabies Vaccines Market, By Distribution Channel (USD Million)
  • 3.9 Future Market Opportunities
  • 3.10 Global Market Split
  • 3.11 Product Life Line

4 GLOBAL HUMAN RABIES VACCINES MARKET OUTLOOK

  • 4.1 Global Human Rabies Vaccines Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL HUMAN RABIES VACCINES MARKET, BY CELL LINE TYPE

  • 5.1 Overview
  • 5.2 Chick Embryo Cell
  • 5.3 Vero Cell
  • 5.4 BHK Cell
  • 5.5 Others

6 GLOBAL HUMAN RABIES VACCINES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Post-exposure Prophylaxis
  • 6.3 Pre-exposure Prophylaxis

7 GLOBAL HUMAN RABIES VACCINES MARKET, BY DISTRIBUTION CHANNEL

  • 7.1 Overview
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Channel

8 GLOBAL HUMAN RABIES VACCINES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Dow Chemical Company Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of Latin America
  • 8.6 Middle-East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of Middle-East and Africa

9 GLOBAL HUMAN RABIES VACCINES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Developments
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 Sanofi Pasteur
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Product Benchmarking
    • 10.1.4 Key Developments
  • 10.2 Merck & Co.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 GSK
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Bavarian Nordic A/S
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 China National Biotec Group Co.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Wuhan Institute of Biological Products Co.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 The Serum Institute of India Ltd.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Bharat Biotech International Limited
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Valneva SE
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Virbac SA
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12. VERIFIED MARKET INTELLIGENCE

  • 12.1 About Verified Market Intelligence
  • 12.2 Dynamic Data Visualization